Skyrizi (risankizumab-rzaa) – To treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
SKYRIZI DOSAGE AND ADMINISTRATION
150 mg (two 75 mg injections) administered by subcutaneous injection at Week 0, Week 4 and every 12 weeks thereafter.
SKYRIZI INDICATIONS AND USAGE
SKYRIZI is an interleukin-23 antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic
therapy or phototherapy.
SKYRIZI ADVERSE REACTIONS
Most common adverse reactions (≥ 1%) are upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.
SKYRIZI DRUG INTERACTIONS
Avoid use of live vaccines in patients treated with SKYRIZI.